Investigators Workshop: Seizures in Seniors: How Do We Identify New and Innovative Therapies for this Growing Patient Demographic?
This workshop will address the specific therapeutic needs of the fastest growing patient demographic with epilepsy diagnosis: the elderly. Despite the greater incidence of epilepsy in the elderly, as well as the overlapping pathology and increased risk of seizures in patients with Alzheimer’s disease, aged animal models are infrequently used to support antiseizure drug development. This workshop will discuss the pros and cons associated with the identification of therapeutic targets, innovation of preclinical models of aging-related seizures, and the application of comprehensive clinical pharmacology to improve therapeutic management and outcomes for aged patients with epilepsy.
Following participation in this activity, participants will be able to:
- Describe the differences in antiseizure drug tolerability and pharmacokinetics in elderly patients and aged preclinical animal models
- Define the risk of seizures and epilepsy in aged individuals, including those with aging-related neurological conditions such as Alzheimer’s disease
- Discuss the availability, use, and limitations of aged preclinical models for antiseizure drug development and define novel therapeutic targets to control hyperexcitability associated with the most common disorder of aging, Alzheimer’s disease
Moderators: Melissa Barker-Haliski; PhD and Angela Birnbaum, PhD; and Helen Scharfman, PhD
Speakers: Erik Roberson, PhD; Sílvia M. Illamola, PharmD, PhD; and David Alcantara- Gonzalez, PhD